Dr. Peyush Bajpai

Head of Department (HOD)

21 Years of Experience

Medical Oncologist

MD, MBBS, DM

Manipal Hospital, Dwarka, Delhi

English

Consultation Fee ₹ 1100

Book an Appointment

About Dr. Peyush Bajpai

Dr. Peyush Bajpai is a prominent Medical Oncologist with over 21 years of experience.
His expertise lies in managing various types of cancers, including Breast Cancer, Gastrointestinal malignancies (such as Gastric, Colo-rectal, Hepatocellular Carcinoma), Gynecological Malignancies (including Carcinoma Ovary and endometrium), Haematological Malignancies (such as Multiple Myeloma, CLL, and Autologous Bone Marrow Transplant, etc.), Soft-tissue Sarcomas, Osteosarcoma, Thoracic Malignancies (including Lung Carcinoma), Immunotherapy, and Precision Oncology.
Dr. Bajpai’s special interest and proficiency lie in Molecular Oncology, Precision Oncology, Targeted Therapies, and Immunotherapies.
He completed his MBBS from Gorakhpur University in 2003, MD (Medicine) from Chhatrapati Shahu Ji Maharaj University, Kanpur, in 2007, and DM (Medical Oncology) from the Tamil Nadu Dr. M.G.R. Medical University, Chennai, in 2012.
He is a member of the European Society of Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), the Indian Society of Medical and Pediatric Oncology (ISMPO), and the Society for Industrial and Organizational Psychology (SIOP).

Book Your Appointment With Dr. Peyush Bajpai

Get a Treatment Plan Within 1 Hour

Name*

Mobile Number*

Is the above number on WhatsApp? *

Yes

Query

Education

MBBS - Gorakhpur University, 2003
MD (Medicine) - Chhatrapati Shahu Ji Maharaj University, Kanpur, 2007
DM (Medical Oncology) - The Tamil Nadu Dr. M.G.R. Medical University, Chennai, 2012

Awards

Received first prize as a part of a team in a case presentation at the UK Breast Oncoplasty Masterclass.
Received first prize in the All India Quiz at the Lymphoma Leukemia meet in Mumbai, organized by the European Society of Medical Oncology (ESMO).
Received best poster in BTG Hong Kong Prospective evaluation of Musculoskeletal events in patients of CML on Imatinib Mesylate and correlation with electrolyte imbalances.

Paper Published

Bajpai P, Ganesan P. Rajendranath, R. and Sagar TG (2012) CaseReport – “ Rare case of hairy cell leukemia in a patient of head and neck malignancy http://medej.tnmgrmu.ac.in 2 (2).
Kanyakumari V, Ganesan P, Bajpai P (2011) A rare case of peripheral T-cell lymphoma in one-year-old child Indian J Med Paediatr Oncol. 2011 Oct-Dec; 32(4): 227–229.
Methotrexate Induced Acute Encephalopathy-Occurrence on Re-challenge and Response to Aminophylline. Indian J Hematol Blood Transfus 2014 Sep 12;30(Suppl 1):105-7. Epub 2013 Jun 12. Peush Bajpai et al.
Novel formulations of docetaxel, paclitaxel, and doxorubicin in the management of metastatic breast cancer Oncol Lett 2018 Sep 2;16(3):3757-3769. Epub 2018 Jul 2. Peush Bajpai et al.
Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce a Durable Response Peush Bajpai et al. Journal of Gastrointestinal Cancer volume 50, pages 943–946 (2019).
Immune checkpoint inhibitors: Real-world experience from India in advanced solid cancers that have progressed on chemotherapy South Asian J Cancer. 2019 Jan-Mar; 8(1): 65–68. Peush Bajpai et al.
Submitted for Publication: Collusion: The façade and its implications on Total pain management in palliative care -IJPC_81_20 (Indian Journal of palliative care Bajpai, P entitled “Retrospective analysis of adolescent ALL outcomes on BFM 86 protocol in “Lymphoma & Leukemia “(2012) international conference organized by ICONESCON held at Mumbai.
Bajpai, P. et al. Poster presentation: Cardiac Status in Long Term Survivors after Anthracycline Therapy in Lymphoma a prospective study of 141 patients, ICON 2009 Chennai.
Prospective evaluation of musculoskeletal events in patients of Chronic Myeloid Leukemia – Chronic Phase treated with Imatinib mesylate AND possible correlation with electrolyte imbalances. The Asia-Pacific Hematology consortium was held on 22- 23 Feb 2013 at Hong Kong BTG2013 Abstract (20):20-21.
A multi-center, open-label, single-arm, phase IV study of Trastuzumab Emtansine in Indian patients with HER2 positive unresectable locally advanced or metastatic breast cancer who have received prior treatment with Trastuzumab and a taxane.
A multi-center, observational, data collection registry study to monitor the routine clinical use of MABTAS (RITUXIMAB 100 MG / 500 MG CONCENTRATE FOR SOLUTION FOR INFUSION, MANUFACTURED BY INTAS PHARMACEUTICALS LTD) in Indian patients.
A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a Firstline Immunotherapy Treatment in Patients with Low Tumor Burden Follicular Lymphoma.
Coguide for Thesis Diplomate National Board (DNB) Medical Assessment of Toxicity of Chemotherapy in Indian Geriatric patient population and Utility Of CRASH-(Chemotherapy Risk Assessment Scale for high age patient).